Homepage
Author:
Spyre Therapeutics, Inc.
Posted Date:
April 3, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc.
April 3, 2026
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
Spyre Therapeutics, Inc.
March 16, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc.
March 6, 2026
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics, Inc.
February 24, 2026
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics, Inc.
February 19, 2026
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
Spyre Therapeutics, Inc.
February 18, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc.
February 8, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc.
January 27, 2026
